Pfizer Inc. (PFE) Stock Analysis
Pfizer Inc. (NYSE: PFE) is one of the world's largest pharmaceutical companies, discovering and manufacturing drugs across vaccines, oncology, internal medicine, and rare diseases. Investors research Pfizer for its diversified product portfolio, dividend yield, and exposure to both legacy blockbusters and newer growth franchises.
Get a full AI research report on PFE
6-step deep analysis in ~90 seconds. Quick research is free — no signup.
What does Pfizer Inc. do?
Pfizer generates revenue by discovering, developing, and commercializing biopharmaceutical products across three segments: Biopharma (internal medicine, vaccines, oncology), Primary Care (PC1), and Pfizer Ignite. The company earns money through sales of branded drugs like Eliquis (cardiovascular), Prevnar (vaccines), Vyndaqel (rare disease), and Paxlovid (COVID-19), as well as through licensing and partnership agreements. Gross margins of 74.8% reflect the high-margin nature of pharmaceutical manufacturing once drugs reach market.
Bull case
- ✓Forward P/E ratio of 8.60 is substantially below the trailing P/E of 18.56, suggesting market expectations for significant earnings growth in the coming year.
- ✓Dividend yield of 7.07% provides income to shareholders, supported by a diversified product portfolio spanning vaccines, oncology, and rare diseases.
- ✓Operating margin of 31.6% demonstrates strong pricing power and operational efficiency in converting revenue to operating profit.
- ✓Prevnar, Eliquis, and Vyndaqel represent established, high-revenue franchises with demonstrated market durability and pricing resilience.
Bear case
- ✗Debt-to-equity ratio of 71.6% indicates substantial leverage, which constrains financial flexibility and increases refinancing risk in a higher-rate environment.
- ✗Payout ratio of 131.3% exceeds net income, meaning the company is returning more cash to shareholders than it earns, relying on asset sales or debt to fund dividends.
- ✗Quick ratio of 0.852 suggests potential near-term liquidity pressure if obligations come due without sufficient liquid assets to cover them.
- ✗Patent cliffs on major drugs like Eliquis and Prevnar could pressure revenue growth if biosimilar or generic competition accelerates.
- ✗PEG ratio of 2.81 indicates the stock may be priced at a premium relative to expected earnings growth, depending on growth assumptions.
PFE valuation & financial health
Pfizer trades at a trailing P/E of 18.56 but a forward P/E of 8.60, implying the market expects material earnings expansion ahead. The company's net margin of 11.8% and operating margin of 31.6% reflect strong profitability, though the payout ratio of 131% raises questions about dividend sustainability without continued revenue growth or asset monetization. The debt-to-equity ratio of 71.6% is elevated for a mature pharma company, and the quick ratio of 0.852 suggests limited liquid reserves relative to short-term obligations. Return on equity of 8.3% and return on assets of 5.7% are modest, reflecting the capital-intensive nature of the business and high debt load.
The bottom line
Pfizer presents a complex profile: a mature, cash-generative pharma company with a high dividend yield and diversified product portfolio, but also carrying substantial debt and a payout ratio exceeding earnings. The sharp discount of forward P/E to trailing P/E suggests the market is pricing in near-term earnings recovery, but investors should monitor patent cliff risks, debt refinancing costs, and whether earnings growth materializes as expected. Key factors to weigh include the sustainability of the dividend given current payout levels, the competitive landscape for key franchises, and macroeconomic sensitivity of pharmaceutical pricing.
Frequently asked questions
What does Pfizer Inc. do?
Pfizer discovers, develops, manufactures, and sells biopharmaceutical products globally, including vaccines (Prevnar, Abrysvo), cardiovascular drugs (Eliquis), oncology treatments, rare disease therapies (Vyndaqel), and COVID-19 treatments (Paxlovid). The company operates through three segments: Biopharma, Primary Care, and Pfizer Ignite.
Is Pfizer a dividend stock?
Yes, Pfizer offers a dividend yield of 7.07%, making it attractive to income-focused investors. However, the payout ratio of 131% exceeds net income, which means the company is distributing more cash than it earns and may rely on asset sales or debt to sustain the dividend.
What is Pfizer's valuation?
Pfizer trades at a trailing P/E of 18.56 and a forward P/E of 8.60, suggesting the market expects significant earnings growth in the next 12 months. The PEG ratio of 2.81 indicates the stock may be priced at a premium relative to expected growth, depending on assumptions.
What are the main risks for Pfizer stock?
Key risks include patent cliffs on major drugs, a debt-to-equity ratio of 71.6%, a payout ratio exceeding 100%, limited short-term liquidity, and competitive pressures from generics and biosimilars. Regulatory changes and pricing pressures in key markets also pose ongoing risks.
Is PFE overvalued or undervalued?
Valuation depends on whether the company achieves the earnings growth implied by the forward P/E of 8.60. The significant gap between trailing and forward P/E suggests the market is pricing in a recovery, but investors should assess the likelihood of that recovery given patent expirations and competitive dynamics.
How financially healthy is Pfizer?
Pfizer is profitable with strong operating margins (31.6%) and gross margins (74.8%), but carries elevated debt (71.6% debt-to-equity) and a payout ratio exceeding earnings. The quick ratio of 0.852 indicates limited short-term liquidity, which warrants monitoring in a rising-rate environment.
Research PFE with AI in seconds
Company profile, financials, events, competition, risks and synthesis — automated.
Start free — no signupFor informational purposes only — not investment advice. Analysis is AI-generated from public data and may contain errors. Always do your own research.